FGF21 and Cardiac Physiopathology

Planavila, Anna; Redondo-Angulo, Ibon; Villarroya, Francesc

doi:10.3389/fendo.2015.00133

Cited by 87 publications

(97 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Experimentally induced myocardial hypertrophy or infarction lead to increased expression of FGF21 (ref. 97 ), which might prevent further progression of myocardial damage.…”

Section: Adiponectinmentioning

confidence: 99%

Adipokines and cardiovascular disease: A comprehensive review

Smékal¹,

Václavík²

2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…Experimentally induced myocardial hypertrophy or infarction lead to increased expression of FGF21 (ref. 97 ), which might prevent further progression of myocardial damage.…”

Section: Adiponectinmentioning

confidence: 99%

Adipokines and cardiovascular disease: A comprehensive review

Smékal¹,

Václavík²

2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…However, later studies showed that FGF21 is expressed and secreted by cardiac cells in response to various stress conditions, including obesity, type 1 diabetes, fasting, ER stress, inflammation, infarct or hypertrophy, and some cardiovascular diseases [49,50]. In the heart, FGFR1 and KLB have been detected in cardiac cells, where FGF21 exerts protective effects in an autocrine and endocrine fashion.…”

Section: Heart: Fgf21 Exerts Cardioprotective Actionsmentioning

confidence: 99%

“…In the heart, FGFR1 and KLB have been detected in cardiac cells, where FGF21 exerts protective effects in an autocrine and endocrine fashion. The mRNA expression of FGF21 in these cells is driven by the transcriptional activation of Sirtuin1 -peroxisome proliferator-activated receptor a (Sirt1-PPARa) [50]; however, it can also be regulated by ATF4, especially when FGF21 induction is caused by ER or oxidative stress [49,51].…”

Section: Heart: Fgf21 Exerts Cardioprotective Actionsmentioning

confidence: 99%

“…FGF21 protects cardiomyocytes from hypertrophy through a mechanism that involves the activation of the cAMP responsive element binding protein (CREB), the induction of PGC1a expression, and the reduction of the NF-kB pro-inflammatory pathway [50]. Cardiac FGF21 also induces the expression of anti-oxidant genes such as Ucp3 and superoxide dismutase (Sod2), thus preventing the production of reactive oxygen species (ROS) in cardiac cells and oxidative stress in the heart [52].…”

Section: Heart: Fgf21 Exerts Cardioprotective Actionsmentioning

confidence: 99%

“…Cardiac FGF21 also induces the expression of anti-oxidant genes such as Ucp3 and superoxide dismutase (Sod2), thus preventing the production of reactive oxygen species (ROS) in cardiac cells and oxidative stress in the heart [52]. In an autocrine fashion, FGF21 modulates cardiac lipid homeostasis [49] and protects against diabetes-induced cardiomyopathy by activating the ERK-p38MAPK-AMPK pathway [50]. Finally, as an endocrine peptide, FGF21 can also inhibit cardiomyocyte apoptosis, thus reducing damage to the heart [53,54].…”

Section: Heart: Fgf21 Exerts Cardioprotective Actionsmentioning

confidence: 99%

See 2 more Smart Citations

Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds

Pérez-Martí

Sandoval

Marrero

et al. 2016

Hormone Molecular Biology and Clinical Investigation

View full text Add to dashboard Cite

Abstract:Obesity is a worldwide health problem mainly due to its associated comorbidities. Fibroblast growth factor 21 (FGF21) is a peptide hormone involved in metabolic homeostasis in healthy individuals and considered a promising therapeutic candidate for the treatment of obesity. FGF21 is predominantly produced by the liver but also by other tissues, such as white adipose tissue (WAT), brown adipose tissue (BAT), skeletal muscle, and pancreas in response to different stimuli such as cold and different nutritional challenges that include fasting, high-fat diets (HFDs), ketogenic diets, some amino acid-deficient diets, low protein diets, high carbohydrate diets or specific dietary bioactive compounds. Its target tissues are essentially WAT, BAT, skeletal muscle, heart and brain. The effects of FGF21 in extra hepatic tissues occur through the fibroblast growth factor receptor (FGFR)-1c together with the co-receptor β-klotho (KLB). Mechanistically, FGF21 interacts directly with the extracellular domain of the membrane bound cofactor KLB in the FGF21-KLB-FGFR complex to activate FGFR substrate 2α and ERK1/2 phosphorylation. Mice lacking KLB are resistant to both acute and chronic effects of FGF21. Moreover, the acute insulin sensitizing effects of FGF21 are also absent in mice with specific deletion of adipose KLB or FGFR1. Most of the data show that pharmacological administration of FGF21 has metabolic beneficial effects. The objective of this review is to compile existing information about the mechanisms that could allow the control of endogenous FGF21 levels in order to obtain the beneficial metabolic effects of FGF21 by inducing its production instead of doing it by pharmacological administration.

show abstract

Role of serum cytokines in the prediction of heart failure in patients with coronary artery disease

Hou,

Sun,

Zhao

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

AimsCoronary artery disease (CAD) is the most common cause of heart failure (HF). This study aimed to identify cytokine biomarkers for predicting HF in patients with CAD.Methods and resultsTwelve patients with CAD without HF (CAD‐non HF), 12 patients with CAD complicated with HF (CAD‐HF), and 12 healthy controls were enrolled for Human Cytokine Antibody Array, which were used as the training dataset. Then, differentially expressed cytokines among the different groups were identified, and crucial characteristic proteins related to CAD‐HF were screened using a combination of the least absolute shrinkage and selection operator, recursive feature elimination, and random forest methods. A support vector machine (SVM) diagnostic model was constructed based on crucial characteristic proteins, followed by receiver operating characteristic curve analysis. Finally, two validation datasets, GSE20681 and GSE59867, were downloaded to verify the diagnostic performance of the SVM model and expression of crucial proteins, as well as enzyme‐linked immunosorbent assay was also used to verify the levels of crucial proteins in blood samples. In total, 12 differentially expressed proteins were overlapped in the three comparison groups, and then four optimal characteristic proteins were identified, including VEGFR2, FLRG, IL‐23, and FGF‐21. After that, the area under the receiver operating characteristic curve of the constructed SVM classification model for the training dataset was 0.944. The accuracy of the SVM classification model was validated using the GSE20681 and GSE59867 datasets, with area under the receiver operating characteristic curve values of 0.773 and 0.745, respectively. The expression trends of the four crucial proteins in the training dataset were consistent with those in the validation dataset and those determined by enzyme‐linked immunosorbent assay.ConclusionsThe combination of VEGFR2, FLRG, IL‐23, and FGF‐21 can be used as a candidate biomarker for the prediction and prevention of HF in patients with CAD.

show abstract

FGF21 and Cardiac Physiopathology

Cited by 87 publications

References 59 publications

Adipokines and cardiovascular disease: A comprehensive review

Adipokines and cardiovascular disease: A comprehensive review

Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds

Role of serum cytokines in the prediction of heart failure in patients with coronary artery disease

Contact Info

Product

Resources

About